fullscreen

eFinder

eFinder

Home › Biopharmaceutical Innovation › Article

This pharma name targeting aging has soared this year. BTIG thinks it can double from here

Cnbc · · 263 words · By Liz Napolitano
Biopharmaceutical Innovation Financial Investment Opportunity
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Biopharmaceutical Innovation

BioAge Labs could more than double amid the release of more data on its anti-inflammation and weight loss drugs over the next year, according to BTIG.

Claims checked 6
Techniques found 1
Topics 2

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center100%
Right0%

1 source compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

BioAge Labs could more than double amid the release of more data on its anti-inflammation and weight loss drugs over the next year, according to BTIG.

Why it matters

The investment firm initiated coverage of the biopharmaceutical name with a buy rating.

Common ground

It also set a $40 price target on shares, implying 120% upside from Tuesday's close.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/05/13/this-drug-maker-could-see-shares-double-on-new-d…

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 80% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 6 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

info Single Source 4
verified Verified By Reference 1
check_circle Corroborated 1
info
Claim 1: “Of the seven analysts covering BioAge Labs, five have a buy or strong buy on the stock, LSEG data shows.”
SINGLE SOURCE
The provided evidence for this claim consists only of dictionary definitions for the word 'according' and does not contain any LSEG data or analyst ratings for BioAge Labs.
travel_explore
web search NEUTRAL — Phrasal verb accord with something (Definition of according from the Cambridge Advanced Learner's Dictionary & Thesaurus © Cambridge University Press)
https://dictionary.cambridge.org/dictionary/english/accordin…
travel_explore
web search NEUTRAL — The term according to can be used to attribute something reported — according to the news, the airports are closed (even though according to your friend, they're still open). It also refers to agreeme…
https://www.dictionary.com/browse/according
travel_explore
web search NEUTRAL — Definition of 'according' according in American English (əˈkɔrdɪŋ ) adjective agreeing; in harmony
https://www.collinsdictionary.com/us/dictionary/english/acco…
info
Claim 2: “It also set a $40 price target on shares”
SINGLE SOURCE
The provided evidence for this claim consists of general descriptions of BTIG's business model and LinkedIn profile; none of the sources mention a $40 price target for BioAge Labs.
travel_explore
web search NEUTRAL — BTIG is a global financial services firm specializing in investment banking, institutional trading, research and related brokerage services.
https://www.btig.com/
travel_explore
web search NEUTRAL — Jan 13, 2026 · BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more …
https://ir.usbank.com/news-events/news/news-details/2026/U-S…
travel_explore
web search NEUTRAL — Fueled by our passion to help maximize results for our institutional and corporate clients, BTIG offers personalized multi-asset class execution, expertise and insights worldwide.
https://www.linkedin.com/company/btig_2/
verified
Claim 3: “A newer drug called BGE-105 also promises to propel BioAge shares higher, according to BTIG.”
VERIFIED BY REFERENCE
Wikipedia explicitly identifies BGE-105 as a drug licensed to BioAge Labs (originally AMG 986), and BioSpace/other news sources confirm its development for muscle aging.
travel_explore
web search NEUTRAL — Azelaprag (original Amgen development code AMG 986, subsequently licensed to BioAge Labs and renamed BGE-105) is a drug which is a selective, small-molecule agonist for the apelin receptor.
https://en.wikipedia.org/wiki/Azelaprag
travel_explore
web search NEUTRAL — About BioAge Labs, Inc. BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging.
https://www.biospace.com/bioage-labs-announces-plans-for-pha…
travel_explore
web search NEUTRAL — BioAge’s first clinical trial of BGE-105, planned for initiation in the first quarter of 2022 under the existing IND, will be a Phase 1 study comparing the pharmacodynamic effects of BGE-105 in humans…
https://longevity.technology/news/bioage-licenses-amgen-drug…
info
Claim 4: “Shares have jumped 38% in the year to date”
SINGLE SOURCE
While stock data is provided, none of the sources explicitly state a '38% jump year-to-date'. One source mentions a 159.38% rise from an unspecified point and another mentions a price target increase, but neither confirms the specific YTD percentage claimed.
travel_explore
web search NEUTRAL — Find the latest BioAge Labs, Inc. (BIOA) stock quote, history, news and other vital information to help you with your stock trading and investing.
https://ca.finance.yahoo.com/quote/BIOA/
travel_explore
web search NEUTRAL — The average one-year price target for BioAge Labs (NasdaqGS:BIOA) has been revised to $9.86 / share. This is an increase of 20.83% from the prior estimate of $8.16 dated November 7, 2025. The ...
https://www.msn.com/en-us/money/topstocks/bioage-labs-bioa-p…
travel_explore
web search NEUTRAL — Since then, Bioage Labs Inc's stock price has risen over 159.38% to $7.47 now. The 52-week high stock price for BIOA is $23.72, representing a 217.54% increase from the current share price, occurred o…
https://stockscan.io/stocks/BIOA/price-history
info
Claim 5: “The investment firm [BTIG] initiated coverage of the biopharmaceutical name with a buy rating.”
SINGLE SOURCE
The claim is reported by CNBC, but the other provided web search results only describe BTIG as a company and its acquisition by U.S. Bancorp, without confirming the specific initiation of coverage for BioAge Labs.
travel_explore
web search NEUTRAL — BTIG is a global financial services firm specializing in investment banking, institutional trading, research and related brokerage services.
https://www.btig.com/
travel_explore
web search NEUTRAL — Jan 13, 2026 · BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more …
https://ir.usbank.com/news-events/news/news-details/2026/U-S…
travel_explore
web search NEUTRAL — Jan 13, 2026 · U.S. Bancorp said on Tuesday it would buy Wall Street brokerage BTIG for up to $1 billion in cash and stock, snapping up a partner to bolster its capital markets presence.
https://www.reuters.com/business/finance/us-bancorp-buy-fina…
+ 1 more evidence source
check_circle
Claim 6: “The analyst pointed to BGE-102, an oral therapy targeting age-related inflammation, as the firm's main value driver.”
CORROBORATED
Multiple independent sources (Globe Newswire and HitGen) confirm that BioAge Labs is developing BGE-102 as an oral therapy targeting NLRP3 for metabolic and age-related diseases.
travel_explore
web search NEUTRAL — EMERYVILLE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic di…
https://ir.bioagelabs.com/news-releases/news-release-details…
travel_explore
web search NEUTRAL — BioAge to host conference call and webcast today at 8:00 AM ET to discuss BGE-102 results EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Comp…
https://www.biospace.com/press-releases/bioage-reports-posit…
travel_explore
web search NEUTRAL — BioAge identified NLRP3 as a therapeutic target for metabolic and age-related diseases and sought to develop novel inhibitors, leading to the successful collaboration with HitGen. BGE-102 was develope…
https://www.hitgen.com/en/news-details-458.html
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.